ABBV · News · 20260824N
Revenue Performance and Mix
AbbVie Inc. · 2026-08-24 · Importance 69 · Surprise 64 · No source text
AbbVie’s second-quarter 2026 net revenue increased 10.2% year over year to $16.990 billion, exceeding the materiality threshold and qualifying under the 10% change rule. Immunology demand for Skyrizi and Rinvoq more than offset declining Humira sales following loss of exclusivity. Neuroscience revenue increased 20.3%, providing an additional major growth contribution. The reporting characterizes AbbVie’s diversified portfolio across immunology, oncology, neuroscience, aesthetics, and eye care as supporting continued market positioning.
Key facts
- Q2 2026 net revenue: up 10.2% to $16.990 billion. source
- Neuroscience revenue increased 20.3%. source
- Growth was primarily driven by the immunology drugs Skyrizi and Rinvoq, which more than offset declines in Humira sales. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +9.3% | Q2 2026 net revenue: up 10.2% to $16.990 billion. |